Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders

BACKGROUND OF THE INVENTION

Compounds of Formula I:

<img file="AU3409697A_D0001.tif" />

<img file="AU3409697A_D0002.tif" />

are structurally novel antiepileptic compounds that are highly effective anticonvulsants in animal tests (Maryanoff, B.E, Nortey, S.O., Gardocki, J.F., Shank, R.P. and Dodgson, S.P. J. Med. Chem. 3 0. 880887, 1987; Maryanoff, B.E., Costanzo, M.J., Shank, R.P., Schupsky, J.J., Ortegon, M.E., and Vaught J.L. Bioorganic &amp; Medicinal Chemistry

Letters 3, 2653-2656, 1993, McComsey, D.F. and Maryanoff, B.E., J. Org. Chem. 1995). These compounds are covered by three US Patents: Nos.4,513,006, 5,384,327 and 5,498,629. One of these compounds 2,3:4,5-bis-O-(l-methylethylidene)-fi-D-fructopyranose sulfamate known as topiramate has been demonstrated in clinical trials of human epilepsy to be effective as adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures (E. FAUGHT, BJ. WILDER, R.E. RAMSEY, R.A. REIFE, L D. KRAMER, G.W. PLEDGER, R.M. KARIM et. al., Epilepsia 36 (S4) 33,1995; S.K. SACHDEO, R.C. SACHDEO, R.A. REIFE, P.

LIM and G. PLEDGER, Epilepsia 36 (S4) 33, 1995), and is currently marketed for the treatment of simple and complex partial seizure

<img file="AU3409697A_D0003.tif" />

<img file="AU3409697A_D0004.tif" />

•. \ c

<img file="AU3409697A_D0005.tif" />

<img file="AU3409697A_D0006.tif" />

WO 98/00123

PCT/US97/10949 epilepsy with or without secondary generalized seizures in Great Britain, Finland, the United States and Sweden and applications for regulatory approval are presently pending in numerous countries throughout the world.

Compounds of Formula I were initially found to possess anticonvulsant activity in the traditional maximal electroshock seizure (MES) test in mice (SHANK, R.P., GARDOCKI, J.F., VAUGHT, J.L., DAVIS, C.B., SCHUPSKY, JJ., RAFFA, R.B., DODGSON, S J., NORTEY, S.O., and MARYANOFF, B.E., Epilepsia 3 5 450-460, 1994). Subsequent studies revealed that Compounds of Formula I were also highly effective in the MES test in rats. More recently topiramate was found to effectively block seizures in several rodent models of epilepsy (J. NAKAMURA, S. TAMURA, T. KANDA, A. ISHII, K. ISHIHARA, T.

SERIKAWA, J. YAMADA, and M. SASA, Eur. J. Pharmacol. 254 83-89, 1994), and in an animal model of kindled epilepsy (A. WAUQUIER and S. ZHOU, Epilepsy Res. 24, 73-77. 1996 in press).

<img file="AU3409697A_D0007.tif" />

Recent preclinical studies on topiramate have revealed previously unrecognized pharmacological properties which suggest that topiramate should be effective in treating manic-depressive bipolar disorder (MDBD).

DISCLOSURE OF THE INVENTION

Accordingly, it has been found that compounds of the following formula I:

<img file="AU3409697A_D0008.tif" />

<img file="AU3409697A_D0009.tif" />

WO 98/00123

PCT/US97/10949

<img file="AU3409697A_D0010.tif" />

wherein X is O or CH2, and Rj, R2, R3, R4 and R5 are as defined hereinafter are useful in treating manic-depressive bipolar disorder (MDBD).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The sulfamates of the invention are of the following formula (I):

<img file="AU3409697A_D0011.tif" />

wherein i

<img file="AU3409697A_D0012.tif" />

X is CH2 or oxygen;

R1 is hydrogen or alkyl; and

R2, R3» R4 and R5 are independently hydrogen or lower alkoxy, when X is oxygen, R2 and R3 and/or R4 and R5 together may be a methylenedioxy group of the following formula (II):

WO 98/00123

PCT/US97/10949

Aowherein

R.6 and R7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

R1 in particular is hydrogen or alkyl of about 1 to 4 carbons, such as methyl, ethyl and iso-propyl. Alkyl throughout this specification includes straight and branched chain alkyl. Alkyl groups for R2, R3, R4, R5, R6 and R7 are of about 1 to 3 carbons and include methyl, ethyl, iso-propyl and n-propyl.

A particular group of compounds of formula (I) are those wherein X is oxygen and both R2 and R3, and R4 and R5 together are methylenedioxy groups of the formula (II), wherein R6 and R7 are both hydrogen, both alkyl, or combine to form a spiro cyclopentyl or cyclohexyl ring, in particular where R6 and R7 are both alkyl such as methyl. A second group of compounds are those wherein X is CH2 and R4 and R5 are joined to form a benzene ring. A third group of compounds of formula (I) are those wherein both R2 and R3 are hydrogen.

The compounds of formula (I) may be synthesized by the following methods:

<img file="AU3409697A_D0013.tif" />

WO 98/00123

PCT/US97/10949

<img file="AU3409697A_D0014.tif" />

(a) Reaction of an alcohol of the formula RCH2OH with a chlorosulfamate of the formula CISO2NH2 or CISO2NHR1 in the presence of a base such as potassium a-butoxide or sodium hydride at a temperature of about -20° to 25° C and in a solvent such as toluene, THF or dimethylformamide wherein R is a moiety of the following formula (III):

<img file="AU3409697A_D0015.tif" />

(b) Reaction of an alcohol of the formula RCH2OH with sulfurylchloride of the formula SO2CI2 in the presence of a base such as triethylamine or pyridine at a temperature of about -40° to 25° C in a solvent such as diethyl ether or methylene chloride to produce a chlorosulfate of the formula RCH2OSO2CI.

<img file="AU3409697A_D0016.tif" />

The chlorosulfate of the formula RCH2OSO2CI may then be reacted with an amine of the formula R1NH2 at a temperature of abut 40° to 25° C in a solvent such as methylene chloride or acetonitrile to produce a compound of formula (I). The reaction 20 conditions for (b) are also described by T. Tsuchiya et al. in Tet.

Letters, No. 36, p. 3365 to 3368 (1978).

(c) Reaction of the chlorosulfate RCH2OSOC1 with a metal azide such as sodium azide in a solvent such as methylene chloride or acetonitrile yields an azidosulfate of the formula RCH2OSO2N3 as

<img file="AU3409697A_D0017.tif" />

<img file="AU3409697A_D0018.tif" />

<img file="AU3409697A_D0019.tif" />

&lt;' *

<img file="AU3409697A_D0020.tif" />

<img file="AU3409697A_D0021.tif" />

WO 98/00123

PCT/US97/10949 described by M. Hedayatullah in Tet. Lett. p. 2455-2458 (1975). The azidosulfate is then reduced to a compound of formula (I) wherein R1 is hydrogen by catalytic hydrogenation, e.g. with a noble metal and H2 or by heating with copper metal in a solvent such as methanol.

<img file="AU3409697A_D0022.tif" />

The starting materials of the formula RCH2OH may be obtained commercially or as known in the art. For example, starting materials of the formula RCH2OH wherein both R2 and R3, and R4 and R5 are 10 identical and are of the formula (II) may be obtained by the method of R. F. Brady in Carbohydrate Research, Vol. 14, p. 35 to 40 (1970) or by reaction of the trimethylsilyl enol ether of a R6COR7 ketone or aldehyde with fructose at a temperature of about 25° C, in a solvent such a halocarbon, e.g. methylene chloride in the presence of a protic 15 acid such as hydrochloric acid or a Lewis Acid such as zinc chloride.

The trimethylsilyl enol ether reaction is described by G. L. Larson et al in J. Org. Chem. Vol. 38, No. 22, p. 3935 (1973).

Further, carboxylic acids and aldehydes of the formulae RCOOH 20 and RCHO may be reduced to compounds of the formula RCH2OH by standard reduction techniques, e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a temperature of about 0° to 100° C, e.g. as described by H.O. House in Modem Synthetic

Reactions, 2nd Ed., pages 45 to 144 (1972).

<img file="AU3409697A_D0023.tif" />

WO 98/00123

PCT/US97/10949

The compounds of formula I: may also be made by the process disclosed US Patent: No.4,513,006, which is incorporated by reference herein.

The compounds of formula I include the various individual isomers as well as the racemates thereof, e.g., the various alpha and beta attachments, i.e., below and above the plane of the drawing, of R2, R3, R4 and R5 on the 6-membered ring. Preferably, the oxygens of the methylenedioxy group (II) are attached on the same side of 10 the 6-membered ring.

<img file="AU3409697A_D0024.tif" />

Manic-depressive bipolar disorder is a progressive psychiatric disorder of unknown etiology (F. GOODWIN and K.R. JAMISON, ManicDepressive Illness, Oxford University Press, New York, 1990).;

however, recurrences of manic-depressive illness have been hypothesized to be caused by electrophysiologic kindling (F. GOODWIN and K.R. JAMISON, Manic-Depressive Illness, Oxford University Press, New York, pp 405-407, 1990). Topiramate has been shown to be effective in blocking kindled seizures in rats; A.

WAUQUIER and S. ZHOU, Epilepsy Res. 24 73-77, 1996 in press).

For treating manic-depressive bipolar disorder, a compound of formula (I) may be employed at a daily dosage in the range of about 50 to 200 mg, usually in two divided doses, for an average adult human. A unit dose would contain about 25 to 100 mg of the active ingredient.

f

<img file="AU3409697A_D0025.tif" />

WO 98/00123

PCT/US97/10949

<img file="AU3409697A_D0026.tif" />

To prepare the pharmaceutical compositions of this invention, one or more sulfamate compounds of formula (I) are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, by suppository, or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. Suppositories may be prepared, in which case cocoa butter could be used as the carrier. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent. The tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, .- I

<img file="AU3409697A_D0027.tif" />

<img file="AU3409697A_D0028.tif" />

WO 98/00123

PCT/US97/10949 sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, ₍ polyethylene glycol, synthetic iron oxide, and polysorbate 80.

The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder injection, teaspoonful, suppository and the like from about 25 to about 100 mg of the active ingredient.

j

-i

<img file="AU3409697A_D0029.tif" />

<img file="AU3409697A_D0030.tif" />

<img file="AU3409697A_D0031.tif" />

WO 98/00123

PCT/US97/10949